Horizon Pharma Buys River Vision for $145 Million and Unspecified Earn-Out

San Diego – May 10, 2017 – Cooley advised Horizon Pharma on its acquisition of River Vision and its development-stage eye medicine teprotumumab for approximately $145 million plus potential future milestone and earn-out payments.

“This acquisition is an important step in our strategy of pursuing and acquiring development-stage medicines targeting rare diseases,” said Timothy P. Walbert, Horizon’s chairman, president and CEO, in a news release. “With no approved medicines to treat thyroid eye disease, there is a significant unmet treatment need among the approximately 10,000 patients in the United States with moderate to severe disease and we look forward to beginning the pivotal study with teprotumumab in the second half of this year.”

Horizon, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.

Cooley helped take Horizon public in 2011 and has represented Horizon on nine publicly announced acquisitions and numerous credit, debt and equity financings, including its largest acquisition to date – the acquisition of Hyperion Therapeutics for $1.1 billion. In 2016, Cooley advised the company on its $800 million acquisition of Raptor Pharmaceutical.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.